<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218969</url>
  </required_header>
  <id_info>
    <org_study_id>Pro#00016705</org_study_id>
    <nct_id>NCT03218969</nct_id>
  </id_info>
  <brief_title>Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist</brief_title>
  <acronym>RLS-Ecopipam</acronym>
  <official_title>Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Ondo, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Restless Legs Syndrome Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, double blinded cross-over study of the D1 antagonist ecopipam treat
      patients currently having dopamine agonist induced augmentation in restless legs syndrome.
      Each arm is 6 weeks composed of an unforced titration up to 100mg/day separated by a 2-week
      wash-out period. Efficacy points will include the IRLS, augmentation scales, sleep scales,
      clinical impressions and fatigue/mood scales.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, exploratory proof of concept, cross-over trial of the D1 antagonist
      ecopipam for subjects with augmented Restless legs syndrome (RLS). Investigators will recruit
      10 subjects taking dopamine agonists for RLS who are currently experiencing augmentation. The
      goal is to have 8 completers. There is no power analysis as this is an exploratory study and
      there is no previous data on treatment of augmentation. &quot;Meaningful improvement&quot; is not even
      established. A safety analysis will be done after 5 subjects have been enrolled. Duration of
      study and is based mostly on contracted drug availability for this pilot study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2017</start_date>
  <completion_date type="Anticipated">October 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International RLS Rating scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Augmentation severity scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour RLS diary</measure>
    <time_frame>Day 0 (visit 1) to end of each treatment arm (6 weeks)</time_frame>
    <description>diary of RLS symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>From start of each treatment arm through one week after treatment withdrawal</time_frame>
    <description>scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hamilton depresion scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </other_outcome>
  <other_outcome>
    <measure>MOS sleep scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Fatigue severity scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Epworth sleep scale</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum chemistry (liver enzymes ALT and AST)</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>safety assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>safety assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical/Neurological exam</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>safety assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>12 lead ECG</measure>
    <time_frame>baseline to end of each treatment arm (6 weeks)</time_frame>
    <description>safety assessment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <condition>Augmentation</condition>
  <arm_group>
    <arm_group_label>Study period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by
Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by
Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by
Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by
Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ecopipam</intervention_name>
    <description>oral drug in subjection currently experiencing dopamine agonist induced augmentation</description>
    <arm_group_label>Study period 1</arm_group_label>
    <arm_group_label>Study period 2</arm_group_label>
    <other_name>PSYRX101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Study period 1</arm_group_label>
    <arm_group_label>Study period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide consent to participate in the study

          -  Individuals of either sex, 21-80 years of age

          -  Clinically defined Restless Leg Syndrome, and problematic augmentation currently on
             monotherapy with dopaminergic treatment.

        Exclusion Criteria:

          -  Current use of Opioid medications

          -  Clinical relevant depression or other medical problems that in the opinion of the
             investigator would not allow for safe completion of the protocol.

          -  Suicidal ideation

          -  History of epilepsy

          -  Current MAO inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G. Ondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William G. Ondo, MD</last_name>
    <phone>713- 363-8184</phone>
    <email>wondo@houstonmethodist.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Titilayo Olubajo</last_name>
    <phone>713-363-8390</phone>
    <email>tolubajo@houstonmethodist.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>William Ondo, MD</investigator_full_name>
    <investigator_title>HMRI Principal &amp; Sponsor Investigator: Ondo</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecopipam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

